{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:23:31Z","timestamp":1789521811488,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bristol-Myers Squibb K.K. and Ono Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We aimed to reveal the effect of abatacept (ABT) on atherosclerosis in rheumatoid arthritis (RA) patients, 3-year efficacy for arthritis, and safety in a population of older vs. younger patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this open-label, prospective, observational study, patients were stratified into four groups: younger (20\u201364 years old) and older (\u2265\u200965 years) patients taking ABT (AY and AO) and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (CY and CO). Primary endpoints were change from baseline in mean intima-media thickness (IMT) of the common carotid artery, IMT max (bulbus, bifurcation, and internal and common carotid artery), and plaque score at Week 156. Disease activity, retention rate, and adverse effects were also evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The ABT group (AY\u2009+\u2009AO) tended to have smaller increases in mean IMT, max IMT, and plaque score than the csDMARD group (CY\u2009+\u2009CO) at Week 156, although the differences between groups were not statistically significant. Multivariate analysis showed significantly lower increases in plaque score with ABT than with csDMARDs, only when considering disease activity at 156 weeks (<jats:italic>p<\/jats:italic>\u2009=\u20090.0303). Proportions of patients with good or good\/moderate European League Against Rheumatism response were higher in the ABT group, without significant difference between older and younger patients. No significant differences were observed in ABT retention rates between older and younger patients. Serious adverse effects, especially infection, tended to be more frequent with ABT than with csDMARDs, although no significant differences were found.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ABT may decelerate atherosclerosis progression and may be useful for patients with high risk of cardiovascular disease, such as older patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number:<\/jats:title>\n                <jats:p>UMIN000014913.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-024-03323-8","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T03:51:04Z","timestamp":1713325864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study"],"prefix":"10.1186","volume":"26","author":[{"given":"Zento","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"3323_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","volume":"8","author":"Q Ding","year":"2023","unstructured":"Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M, et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct Target Ther. 2023;8:68. https:\/\/doi.org\/10.1038\/s41392-023-01331-9.","journal-title":"Signal Transduct Target Ther"},{"key":"3323_CR2","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-216515","volume":"78","author":"S Safiri","year":"2019","unstructured":"Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78:1463\u201371. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216515.","journal-title":"Ann Rheum Dis"},{"key":"3323_CR3","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/14397595.2019.1682776","volume":"30","author":"M Kojima","year":"2020","unstructured":"Kojima M, Nakayama T, Tsutani K, Igarashi A, Kojima T, Suzuki S, et al. Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey. Mod Rheumatol. 2020;30:941\u20137. https:\/\/doi.org\/10.1080\/14397595.2019.1682776.","journal-title":"Mod Rheumatol"},{"key":"3323_CR4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrrheum.2013.92","volume":"9","author":"AMH Boots","year":"2013","unstructured":"Boots AMH, Maier AB, Stinissen P, Masson P, Lories RJ, De Keyser F. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:604\u201313. https:\/\/doi.org\/10.1038\/nrrheum.2013.92.","journal-title":"Nat Rev Rheumatol"},{"key":"3323_CR5","doi-asserted-by":"publisher","first-page":"e002468","DOI":"10.1136\/bmjopen-2012-002468","volume":"3","author":"B Ng","year":"2013","unstructured":"Ng B, Chu A, Khan MM. A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers. BMJ Open. 2013;3:e002468. https:\/\/doi.org\/10.1136\/bmjopen-2012-002468.","journal-title":"BMJ Open"},{"key":"3323_CR6","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275\u201385. https:\/\/doi.org\/10.1001\/jama.295.19.2275.","journal-title":"JAMA"},{"key":"3323_CR7","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1002\/art.21386","volume":"52","author":"J Listing","year":"2005","unstructured":"Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403\u201312. https:\/\/doi.org\/10.1002\/art.21386.","journal-title":"Arthritis Rheum"},{"key":"3323_CR8","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1136\/ard-2023-224049","volume":"82","author":"MD Russell","year":"2023","unstructured":"Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82:1059\u201367. https:\/\/doi.org\/10.1136\/ard-2023-224049.","journal-title":"Ann Rheum Dis"},{"key":"3323_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/pds.2046","volume":"20","author":"J Askling","year":"2011","unstructured":"Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidermiol Drug Saf. 2011;20:119\u201330. https:\/\/doi.org\/10.1002\/pds.2046.","journal-title":"Pharmacoepidermiol Drug Saf"},{"key":"3323_CR10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1101\u201336. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210708.","journal-title":"Ann Rheum Dis"},{"key":"3323_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/1744666x.2019.1579642","volume":"15","author":"M Pombo-Suarez","year":"2019","unstructured":"Pombo-Suarez M, Gomez-Reino JJ. Abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15:319\u201326. https:\/\/doi.org\/10.1080\/1744666x.2019.1579642.","journal-title":"Expert Rev Clin Immunol"},{"key":"3323_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","volume":"21","author":"TA Simon","year":"2019","unstructured":"Simon TA, Boers M, Hochberg M, Baker N, Skovron ML, Ray N, et al. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. Arthritis Res Ther. 2019;21:228. https:\/\/doi.org\/10.1186\/s13075-019-1992-x.","journal-title":"Arthritis Res Ther"},{"key":"3323_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/14397595.2018.1524998","volume":"29","author":"M Harigai","year":"2019","unstructured":"Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, et al. Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. Mod Rheumatol. 2019;29:747\u201355. https:\/\/doi.org\/10.1080\/14397595.2018.1524998.","journal-title":"Mod Rheumatol"},{"key":"3323_CR14","doi-asserted-by":"publisher","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-37. https:\/\/doi.org\/10.1093\/eurjpc\/zwab154 [Published correction appears in Eur Heart J. 2022;43:4468].","DOI":"10.1093\/eurjpc\/zwab154"},{"key":"3323_CR15","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/s2665-9913(20)30221-6","volume":"3","author":"R Hansildaar","year":"2021","unstructured":"Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol. 2021;3:e58\u201370. https:\/\/doi.org\/10.1016\/s2665-9913(20)30221-6.","journal-title":"Lancet Rheumatol"},{"key":"3323_CR16","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.15420\/ecr.2020.44","volume":"16","author":"AM Kerola","year":"2021","unstructured":"Kerola AM, Rollefstad S, Semb AG. Atherosclerotic cardiovascular disease in rheumatoid arthritis: impact of inflammation and antirheumatic treatment. Eur Cardiol. 2021;16:e18. https:\/\/doi.org\/10.15420\/ecr.2020.44.","journal-title":"Eur Cardiol"},{"key":"3323_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00296-016-3638-5","volume":"37","author":"J van den Hoek","year":"2017","unstructured":"van den Hoek J, Boshuizen HC, Roorda LD, Tijhuis GJ, Nurmohamed MT, van den Bos GAM, et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int. 2017;37:487\u201393. https:\/\/doi.org\/10.1007\/s00296-016-3638-5.","journal-title":"Rheumatol Int"},{"key":"3323_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3899\/jrheum.161154","volume":"44","author":"E Myasoedova","year":"2017","unstructured":"Myasoedova E, Gabriel SE, Matteson EL, Davis JM 3rd, Therneau TM, Crowson CS. Decreased cardiovascular mortality in patients with incident rheumatoid arthritis (RA) in recent years: dawn of a new era in cardiovascular disease in RA? J Rheumatol. 2017;44:732\u20139. https:\/\/doi.org\/10.3899\/jrheum.161154.","journal-title":"J Rheumatol"},{"key":"3323_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41584-021-00593-3","volume":"17","author":"F Atzeni","year":"2021","unstructured":"Atzeni F, Rodr\u00edguez-Carrio J, Popa CD, Nurmohamed MT, Sz\u0171cs G, Szekanecz Z. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:270\u201390. https:\/\/doi.org\/10.1038\/s41584-021-00593-3.","journal-title":"Nat Rev Rheumatol"},{"key":"3323_CR20","doi-asserted-by":"publisher","first-page":"e7309","DOI":"10.1016\/j.amjmed.2013.02.016","volume":"126","author":"DH Solomon","year":"2013","unstructured":"Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-\u03b1 blockade with nonbiologic DMARDs. Am J Med. 2013;126:e7309\u201317. https:\/\/doi.org\/10.1016\/j.amjmed.2013.02.016.","journal-title":"Am J Med"},{"key":"3323_CR21","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","volume":"168","author":"MM Ewing","year":"2013","unstructured":"Ewing MM, Karper JC, Abdul S, de Jong RCM, Peters HAB, de Vries MR, et al. T-cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol. 2013;168:1965\u201374. https:\/\/doi.org\/10.1016\/j.ijcard.2012.12.085.","journal-title":"Int J Cardiol"},{"key":"3323_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/mps4040083","volume":"4","author":"T Ishigami","year":"2021","unstructured":"Ishigami T, Nanki T, Sugawara T, Uchida K, Takeda H, Sawasaki T, et al. Rationale and design of the Orencia atherosclerosis and rheumatoid arthritis study (ORACLE Arthritis Study): implications of biologics against rheumatoid arthritis and the vascular complications, subclinical atherosclerosis. Methods Protoc. 2021;4:83. https:\/\/doi.org\/10.3390\/mps4040083.","journal-title":"Methods Protoc"},{"key":"3323_CR23","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s40744-021-00356-2","volume":"8","author":"S Muraoka","year":"2021","unstructured":"Muraoka S, Yamada Z, Kawazoe M, Hirose W, Kono H, Yasuda S, et al. Abatacept is efficacious in the treatment of older patients with csDMARD-refractory rheumatoid arthritis: a prospective, multicenter, observational study. Rheumatol Ther. 2021;8:1585\u2013601. https:\/\/doi.org\/10.1007\/s40744-021-00356-2.","journal-title":"Rheumatol Ther"},{"key":"3323_CR24","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381. https:\/\/doi.org\/10.1002\/art.27584.","journal-title":"Arthritis Rheum"},{"key":"3323_CR25","unstructured":"Bristol-Myers Squibb. ORENCIA (abatacept) [package insert]. U.S. Food and Drug Administration website. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125118s171lbl.pdf. Accessed 12 Oct 2023."},{"key":"3323_CR26","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1161\/01.str.21.11.1567","volume":"21","author":"N Handa","year":"1990","unstructured":"Handa N, Matsumoto M, Maeda H, Hougaku H, Ogawa S, Fukunaga R, et al. Ultrasonic evaluation of early carotid atherosclerosis. Stroke. 1990;21:1567\u201372. https:\/\/doi.org\/10.1161\/01.str.21.11.1567.","journal-title":"Stroke"},{"key":"3323_CR27","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","volume":"75","author":"J Zhang","year":"2016","unstructured":"Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1813\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207870.","journal-title":"Ann Rheum Dis"},{"key":"3323_CR28","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3899\/jrheum.170926","volume":"45","author":"Y Jin","year":"2018","unstructured":"Jin Y, Kang EH, Brill G, Desai RJ, Kim SC. Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J Rheumatol. 2018;45:1240\u20138. https:\/\/doi.org\/10.3899\/jrheum.170926.","journal-title":"J Rheumatol"},{"key":"3323_CR29","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/01.str.26.10.1781","volume":"26","author":"N Handa","year":"1995","unstructured":"Handa N, Matsumoto M, Maeda H, Hougaku H, Kamada T. Ischemic stroke events and carotid atherosclerosis. Results of the Osaka follow-up study for Ultrasonographic Assessment of Carotid Atherosclerosis (the OSACA Study). Stroke. 1995;26:1781\u20136. https:\/\/doi.org\/10.1161\/01.str.26.10.1781.","journal-title":"Stroke"},{"key":"3323_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.atherosclerosis.2011.09.024","volume":"219","author":"M Plichart","year":"2011","unstructured":"Plichart M, Celermajer DS, Zureik M, Helmer C, Jouven X, Ritchie K, et al. Carotid intima-media thickness in plaque-free site, carotid plaques and coronary heart disease risk prediction in older adults. The three-city study. Atherosclerosis. 2011;219:917\u201324. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.09.024.","journal-title":"Atherosclerosis"},{"key":"3323_CR31","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/annrheumdis-2016-210997","volume":"76","author":"EE Arts","year":"2017","unstructured":"Arts EE, Fransen J, Den Broeder AA, van Riel PLCM, Popa CD. Low disease activity (DAS28\u2009\u2264\u20093.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann Rheum Dis. 2017;76:1693\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210997.","journal-title":"Ann Rheum Dis"},{"key":"3323_CR32","doi-asserted-by":"publisher","first-page":"7910","DOI":"10.3390\/ijms24097910","volume":"24","author":"E Gusev","year":"2023","unstructured":"Gusev E, Sarapultsev A. Atherosclerosis and inflammation: insights from the theory of general pathological processes. Int J Mol Sci. 2023;24:7910. https:\/\/doi.org\/10.3390\/ijms24097910.","journal-title":"Int J Mol Sci"},{"key":"3323_CR33","doi-asserted-by":"publisher","first-page":"8379","DOI":"10.3390\/ijms22168379","volume":"22","author":"AV Poznyak","year":"2021","unstructured":"Poznyak AV, Bezsonov EE, Popkova TV, Starodubova AV, Orekhov AN. Immunity in atherosclerosis: focusing on T and B cells. Int J Mol Sci. 2021;22:8379. https:\/\/doi.org\/10.3390\/ijms22168379.","journal-title":"Int J Mol Sci"},{"key":"3323_CR34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4049\/jimmunol.2000455","volume":"207","author":"G Carvajal Alegria","year":"2021","unstructured":"Carvajal Alegria G, Cornec D, Saraux A, Devauchelle-Pensec V, Jamin C, Hillion S, et al. Abatacept promotes regulatory B cell functions, enhancing their ability to reduce the Th1 response in rheumatoid arthritis patients through the production of IL-10 and TGF-\u03b2. J Immunol. 2021;207:470\u201382. https:\/\/doi.org\/10.4049\/jimmunol.2000455.","journal-title":"J Immunol"},{"key":"3323_CR35","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1161\/01.cir.101.25.2883","volume":"101","author":"G Liuzzo","year":"2000","unstructured":"Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000;101:2883\u20138. https:\/\/doi.org\/10.1161\/01.cir.101.25.2883.","journal-title":"Circulation"},{"key":"3323_CR36","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1161\/01.CIR.0000131450.66017.B3","volume":"109","author":"R Gerli","year":"2004","unstructured":"Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, et al. CD4\u2009+\u2009CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation. 2004;109:2744\u20138. https:\/\/doi.org\/10.1161\/01.CIR.0000131450.66017.B3.","journal-title":"Circulation"},{"key":"3323_CR37","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1161\/01.cir.100.21.2135","volume":"100","author":"G Liuzzo","year":"1999","unstructured":"Liuzzo G, Kopecky SL, Frye RL, O\u2019Fallon WM, Maseri A, Goronzy JJ, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation. 1999;100:2135\u20139. https:\/\/doi.org\/10.1161\/01.cir.100.21.2135.","journal-title":"Circulation"},{"key":"3323_CR38","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3899\/jrheum.091176","volume":"37","author":"M Scarsi","year":"2010","unstructured":"Scarsi M, Ziglioli T, Air\u00f2 P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol. 2010;37:911\u20136. https:\/\/doi.org\/10.3899\/jrheum.091176.","journal-title":"J Rheumatol"},{"key":"3323_CR39","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/mr\/roab050","volume":"32","author":"M Harigai","year":"2022","unstructured":"Harigai M, Tsuritani K, Yoshizawa Y, Atsumi T, Tanaka Y. Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance. Mod Rheumatol. 2022;32:508\u201316. https:\/\/doi.org\/10.1093\/mr\/roab050.","journal-title":"Mod Rheumatol"},{"key":"3323_CR40","first-page":"090","volume":"16","author":"T Mochizuki","year":"2021","unstructured":"Mochizuki T, Yano K, Ikari K, Okazaki K. Long-term results of joint damage in patients with rheumatoid arthritis treated with abatacept: 5-year results of a clinical observational study. Int J Clin Rheumatol. 2021;16:090\u20136.","journal-title":"Int J Clin Rheumatol"},{"key":"3323_CR41","first-page":"834","volume":"34","author":"S Kubo","year":"2016","unstructured":"Kubo S, Nakano K, Nakayamada S, Hirata S, Fukuyo S, Sawamukai N, et al. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept leading trial for RA on Imaging Remission (ALTAIR) study. Clin Exp Rheumatol. 2016;34:834\u201341. PMID: 27607196.","journal-title":"Clin Exp Rheumatol"},{"key":"3323_CR42","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00296-016-3631-z","volume":"37","author":"H Kawashima","year":"2017","unstructured":"Kawashima H, Kagami SI, Kashiwakuma D, Takahashi K, Yokota M, Furuta S, et al. Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. Rheumatol Int. 2017;37:369\u201376. https:\/\/doi.org\/10.1007\/s00296-016-3631-z.","journal-title":"Rheumatol Int"},{"key":"3323_CR43","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1080\/14397595.2018.1525019","volume":"29","author":"N Takahashi","year":"2019","unstructured":"Takahashi N, Kojima T, Kida D, Kaneko A, Hirano Y, Fujibayashi T, et al. Clinical effectiveness and long-term retention of abatacept in elderly rheumatoid arthritis patients: results from a multicenter registry system. Mod Rheumatol. 2019;29:910\u20138. https:\/\/doi.org\/10.1080\/14397595.2018.1525019.","journal-title":"Mod Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03323-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T03:53:07Z","timestamp":1713325987000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03323-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3323"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03323-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"assertion":[{"value":"2 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics committee of Faculty of Medicine, Toho University (Approval number: A20114_A17112_A16017_27038), Teikyo University (14\u2013061) and ethics committees of collaborative institutions approved the study protocol. All participants consented to the study upon enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"SM received speaker\u2019s bureau fees from Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Asahikasei Pharma Corp., and Astellas Pharma Inc. MK received speaker fees from Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma Corp., Chugai Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corp., AstraZeneca K.K., GlaxoSmithKline plc., Nippon Boehringer Ingelheim Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Gilead Sciences Inc. WH received speaker fees from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Astellas Pharma Inc., Pfizer Japan Inc., Asahikasei Pharma Corp., Eli Lilly Japan K.K., AbbVie GK, Mitsubishi Tanabe Pharma Corp., Nippon Boehringer Ingelheim Co., Ltd., and Bristol-Myers Squibb Co. HK received grant\/research support from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Asahikasei Pharma Corp., and Teijin Pharma Ltd., and speakers fees from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahikasei Medical Co., Ltd., AbbVie GK, Amgen Inc., Celgene Corp., Gilead Sciences Inc., Mitsubishi Tanabe Pharma Corp., UCB Japan Co. Ltd., Ayumi Pharmaceutical Corp., Daiichi Sankyo Co., Ltd. and Teijin Pharma Ltd. SY received grants support from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Asahikasei Pharma Corp., Ayumi Pharmaceutical Corp., AbbVie GK and Taisho Pharmaceutical Co., Ltd., consultant fees from Eisai Co., Ltd., Asahikasei Pharma Corp., Chugai Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd., and personal fees from AbbVie GK, Chugai Pharmaceutical Co., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Eli Lilly K.K., GlaxoSmithKline plc., and AstraZeneca K.K. TS received research grants from Asahikasei Pharma Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd., and honoraria from AbbVie GK, Asahikasei Pharma Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Corp., Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd. and UCB Japan Co. Ltd. TN received grant\/research support from Chugai Pharmaceutical Co., Ltd, Eisai Co., Ltd., Eli Lilly Japan K.K., Bristol-Myers Squibb Co., Ono Pharmaceutical Co., Ltd., Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma Corp., Ayumi Pharmaceutical Corp, Nippon Kayaku Co., Ltd., AbbVie GK, Sanofi K.K., Teijin Pharma Ltd., Nippon Boehringer Ingelheim Co., Ltd., Taisho Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd. and Shionogi & Co., Ltd., consultant fees from UCB Japan Co., Ltd., Eisai Co., Ltd. and Chugai Pharmaceutical Co., Ltd., and speakers fees from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahikasei Pharma Corp., Eli Lilly Japan K.K., Mylan N.V., AbbVie GK, Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., Ayumi Pharmaceutical Corp., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corp., Kyowa Kirin Co., Ltd., UCB Japan Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., GlaxoSmithKline plc. and Taisho Pharmaceutical Co., Ltd. The remaining author declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}